Last reviewed · How we verify
NCT05693090
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Phase 1 trial testing Tipifarnib in NSCLC. Withdrawn.
27 July 2027
Quick facts
| Lead sponsor | Kura Oncology, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 February 2023 |
| Primary completion | 27 July 2027 |
| Estimated completion | 27 July 2027 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Tipifarnib — full drug profile →
- Osimertinib (osimertinib) — full drug profile →
Conditions studied
- NSCLC — all drugs for NSCLC →
Sponsor
Kura Oncology, Inc. — full company profile →
Who can join
18 and older, any sex, with NSCLC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1a/b, multicenter, open-label, dose escalation (1a) and dose expansion (1b) study. The purpose of this study is to measure safety, tolerability, and preliminary efficacy with the combination of tipifarnib with osimertinib in patients with advanced/metastatic EGFR-mutated non-small cell lung cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05693090
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tipifarnib
Trials testing the same drug.
- NCT06540963 — Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma · Phase 2 · recruiting
- NCT04997902 — Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M · Phase 1, PHASE2 · completed
- NCT04865159 — Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies · Phase 1 · terminated
- NCT04284774 — Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a · Phase 2 · active not recruiting
- NCT03719690 — Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy · Phase 2 · completed
Other recruiting trials for NSCLC
Currently open trials in the same condition.
- NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
- NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting
Other Kura Oncology, Inc. trials
Trials by the same sponsor.
- NCT04997902 — Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M · Phase 1, PHASE2 · completed
- NCT04865159 — Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies · Phase 1 · terminated
- NCT04067336 — First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia · Phase 1, PHASE2 · recruiting
- NCT03719690 — Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy · Phase 2 · completed
- NCT03051035 — First-in-Human Study of KO-947 in Non-Hematological Malignancies · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05693090 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kura Oncology, Inc.
- Last refreshed: 6 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05693090.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing